BridgeBio Pharma, Inc. Presents Data from the ATTRibute-CM Study

 - Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:

• 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients initially randomized to placebo in the ATTRibute-CM study
• 69% risk reduction in ACM/ first CVH through Month 30 compared to placebo (p=0.016) and a 69% risk reduction in ACM through Month 42 (p=0.045) in ATTR-CM participants with the genetic variant p.Val142Ile (V142I, V122I) compared to patients initially randomized to placebo in the ATTRibute-CM study

- This is the first report of clinical benefit of this magnitude observed in this high-risk population with significant unmet need

https://www.globenewswire.com/news-release/2025/11/08/3184066/0/en/Acoramidis-Significantly-Reduces-All-cause-Mortality-in-the-Overall-ATTR-CM-Variant-and-V142I-V122I-Populations.html